Every material Form 8-K Summit Therapeutics Inc. has filed with the SEC since September 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Summit Therapeutics filed a prospectus supplement under its automatic shelf registration statement on Form S-3 and an accompanying 8-K to file a legal opinion from Baker & Hostetler LLP on the legality of the common stock issuance. The filing does not state the number of shares, the price, or the amount of proceeds, so the filing alone does not show the size or dilution effect of the offering.
Prospectus supplement filed November 4, 2026 under Form S-3 (Registration No. 333-296642)
Baker & Hostetler LLP legality opinion filed as Exhibit 5.1, with consent as Exhibit 23.1
Filing does not disclose share count, offering price, or proceeds
On November 4, 2026, Summit Therapeutics stockholders approved raising authorized common shares from 1 billion to 2 billion at a special meeting, and the amendment took effect when filed that day. The same day, the company reported third-quarter 2026 results showing a GAAP net loss of $208.4 million ($0.26 per share), narrower than $231.8 million a year earlier, while the non-GAAP net loss widened to $160.7 million from $101.0 million. Cash and short-term investments were $629.8 million at September 30, 2026, and the $2.0 billion AstraZeneca equity investment completed October 5, 2026, after the quarter ended.
Amendment No. 3 increases authorized common stock by 1,000,000,000 shares to 2,000,000,000; votes for were 658,142,561, against 1,983,511, with 3,134,826 abstentions.
GAAP net loss was $208.4 million, or $(0.26) per share, versus $231.8 million, or $(0.31) per share, a year earlier; non-GAAP net loss was $160.7 million, or $(0.20) per share, versus $101.0 million, or $(0.13).
Cash and short-term investments were $629.8 million at September 30, 2026, down from $713.4 million at December 31, 2025; the company raised $94.1 million through its ATM facility in the third quarter.
AstraZeneca completed a $2.0 billion strategic equity investment on October 5, 2026; the FDA PDUFA goal action date for the ivonescimab BLA is November 14, 2026.
Summit Therapeutics agreed on September 28, 2026 to sell 108,955.3686 shares of Class A Convertible Preferred Stock to AstraZeneca Holdings B.V. for $2.0 billion in gross proceeds, and also signed a separate clinical trial collaboration with AstraZeneca on sonesitatug vedotin combined with ivonescimab. Shareholders would face dilution once the preferred converts into common stock, which is subject to conditions and a registration statement, and the company must redeem the preferred for cash if a required share authorization is not effective within 18 months.
Purchase price of $18,356.14 per preferred share, based on a common stock price of $18.3561; each preferred share converts into 1,000 common shares
Closing is expected within five business days of the Purchase Agreement, subject to customary conditions
Conversion is barred until the later of any Hart-Scott-Rodino waiting period expiration and effectiveness of the authorized share increase charter amendment
Company must file a resale registration statement within 60 days after closing; cash redemption required if the share increase is not effective within 18 months
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Summit Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →